The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
 
Arpit Rao
Leadership - Ankr
Stock and Other Ownership Interests - AstraZeneca
Honoraria - Bayer; Bristol-Myers Squibb; Cardinal Health; Dendreon; Eisai; Lilly; Sanofi
Consulting or Advisory Role - Lilly (Inst)
Speakers' Bureau - Bristol Myers Squibb
Research Funding - Clovis Oncology (Inst); Lilly (Inst); Pfizer/Astellas (Inst); Seattle Genetics/Astellas (Inst)
 
Glenn Heller
No Relationships to Disclose
 
Charles J. Ryan
Honoraria - Bayer; Janssen Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Clovis Oncology (Inst); Dendreon; Myovant Sciences; Roivant
Research Funding - Clovis Oncology (Inst); Genzyme (Inst)
 
David James VanderWeele
Honoraria - Astellas Pharma
Consulting or Advisory Role - Bayer; Clovis Oncology; Exelixis; Janssen
Research Funding - AstraZeneca (Inst); Department of Defense-Prostate Cancer Research Program; Fortis (Inst); Prostate Cancer Foundation
 
Lionel D Lewis
Consulting or Advisory Role - 7 Hills Pharma; G1 Therapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curis (Inst)
Expert Testimony - Amgen
Travel, Accommodations, Expenses - 7 Hills Pharma
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; crispr therapeutics; Editas Medicine; FATE Therapeutics; Geron; Iovance Biotherapeutics; Jounce Therapeutics; MEI Pharma; Myovant Sciences; Nektar; Sangamo Therapeutics
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Verastem
Consulting or Advisory Role - Exelixis; Foundation Medicine
Speakers' Bureau - AstraZeneca; bristol myers squibb; verastem
 
Colleen Watt
No Relationships to Disclose
 
Ronald C. Chen
Consulting or Advisory Role - Abbvie; Accuray; Accuray; Astellas Pharma; Bayer; Blue Earth Diagnostics; Genentech; Janssen; Medivation/Astellas; Myovant Sciences; Pfizer
Research Funding - Accuray
 
Manish Kohli
Employment - nference (I)
Honoraria - Advanced Accelerator Applications
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Genapsys; Tempus
Patents, Royalties, Other Intellectual Property - Patent number: 10982286. Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine
Travel, Accommodations, Expenses - Celgene
 
Pedro C. Barata
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Bayer (Inst); Caris Life Sciences (Inst); Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Merck (Inst); Pfizer (Inst)
 
Benjamin Adam Gartrell
Honoraria - Janssen
Consulting or Advisory Role - Janssen
 
Robert Grubb
No Relationships to Disclose
 
Amylou C. Dueck
Patents, Royalties, Other Intellectual Property - Royalties from licensing fees for a patient symptom questionnaire (MPN-SAF)
 
Yujia Wen
No Relationships to Disclose
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Amgen; AstraZeneca; Clarity Pharmaceuticals; Convergent Therapeutics; Daiichi; Exelixis; ITM Isotope Technologies Munich; Lantheus Medical Imaging; NCCN; Pfizer
Research Funding - Bayer (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst); Progenics (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Bayer; Janssen Oncology; Novartis